MedTrace Logo

Optimizing Treatment on Idiopathic Inflammatory Myopathies

NCT03092180 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-12-05

No results posted yet for this study

Summary

As a T2T, our patients with idiopathic inflammatory myopathies will receive pulse therapies with methyprednisolone and/or human intravenous immunoglobulin, or only methyprednisolone at disease onset.

This scheme is an internal routine protocol of our Service.

Conditions

  • Idiopathic Inflammatory Myopathies

Interventions

DRUG

Intravenous Infusion

Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Samuel K Shinjo, PhD · Universidade de Sao Paulo - Rheumatology Division

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2024-05-06
Completion
2024-12-04

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03092180 on ClinicalTrials.gov